Project Grant R01NS138605

Award Date 5/1/25
Completion Date 4/30/30
Dollars Obligated $532K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $121,554.00 to the University of California, San Diego (UCSD) to investigate the role of the KIF5A gene in amyotrophic lateral sclerosis (ALS). The research aims to: (1) examine the impact of ALS-related KIF5A mutations on the proteotoxic pathway, (2) explore the interactions...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $340,258 to Emory University to conduct research on assessing the contribution of cortical hyperactivity to amyotrophic lateral sclerosis (ALS) phenotypes using a human-derived motor system model. The research aims to elucidate the relationship between cortical hyperexcitability, a...
This $1,938,189 Project Grant award was made by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to Emory University in Atlanta, Georgia. The project aims to expand understanding of the role of chimeric dipeptide repeat proteins (CDPRs) in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by the C9ORF72 gene mutation. Key objectives include: 1) Identifying the complexity, extent, and mechanism of CDPR pathology in...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $558,182 to The Washington University in St. Louis to conduct research on identifying mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS). The key objectives of this research project are to: 1) Compare neurofilament isoforms...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $645,391 to The Trustees of Columbia University in the City of New York to investigate the effects of re-expressing embryonic motor neuron selector transcription factors on amyotrophic lateral sclerosis (ALS) pathology. The project aims to test the hypothesis that changes...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $427,625 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders federal grant program (CFDA 93.853) to The Washington University in St. Louis. The research project aims to develop a novel cellular model for investigating the mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) using directly converted neurons derived from patient...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $460,625 to the University of Massachusetts Medical School to develop mutant-specific antisense oligonucleotides (ASOs) as potential therapeutics for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The key objectives are to: 1) Design and evaluate...
This $251,250 federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to investigate the connection between dysfunction of neuroimmune-related processes and amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) disorders. The research will use a mouse model of mutant TDP-43, a key pathological protein...
This federal Project Grant award of $2,307,075.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research efforts by The Leland Stanford Junior University (Stanford University) to explore novel mechanisms and therapeutic strategies for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson's...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $532,381 to Emory University to comprehensively investigate the molecular mechanisms underlying the role of the KIF5AΔe27 variant in the pathogenesis of amyotrophic lateral sclerosis (ALS).

The research will focus on three specific aims: 1) determining the gain-of-function effects of the KIF5AΔe27 variant in transgenic mouse models and identifying age- and disease-dependent molecular pathway alterations in the spinal cord; 2) examining cargo transport deficits and altered RNA metabolism caused by KIF5AΔe27 in induced pluripotent stem cell-derived motor neurons; and 3) elucidating the molecular determinants and toxicity of KIF5AΔe27 aggregates. This multidisciplinary approach aims to yield critical insights into ALS disease mechanisms and explore innovative therapeutic strategies. The project period spans from May 1, 2025 to April 30, 2030.

Generated 5/13/25, 5:28 AM